

Table 1. Seroconversion rates and vaccine efficacy for serogroup B meningococcal vaccines

Vaccine (reference)	Doses	Vaccinees	Rate of seroconversion following immunisation		FU	Vaccine efficacy mean (95% confidence intervals)	
Norwegian (10)	2	Norway 14-16yr n=171,800	NT		29mo	57.2% (27.7% -?)	
Norwegian (14)	3	Iceland 18 yr n=153	at 12mo FU	84%	NT		
			at 20mo FU	69%			
Cuban (11)	2	Sao Paulo 3mo-6yr n=2.4 million	NT		<1yr	Age	
						3-23mo	-37% (≤-100-73)
						24-47mo	47% (-72-84)
						≥48mo	74% (16-92)
Cuban (12)	2	Rio de Janiero 6mo-9yr n=1.6 million	NT		1yr	Age	
						6-23mo	47% (≤-100-89)
						24-47mo	69% (-45-94)
						≥48mo	82% (40-95)
Cuban (15)	2	Sao Paulo 3mo-6yr n=210	Age		NT		
			3-23mo	22%			
			24-47mo	45%			
			48-83mo	52%			

Vaccine (reference)	Doses	Vaccinees	Rate of seroconversion following immunisation		FU	Vaccine efficacy mean (95% confidence intervals)	
USA (13)	2	Iquique, Chile 1-21yr n=40811	Age 1-4yr 5-21yr	12% 65%	20mo	Age 1-4yr 5-21yr	-39% (≤-100-77) 70% (3-93)
Cuban or Norwegian (16)	3	Santiago, Chile <1-30yr n=543	Age <1yr 2-4yr 17-30yr	Cuban 90% 78% 67%	Norwegian 98% 98% 96%	NT	

FU=follow up, NT=not tested, wk=weeks, mo=months, yr=years